Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their December 31 holdings, data that is available nowhere else. Should you consider Mirati Therapeutics, Inc. (NASDAQ:MRTX) for your portfolio? We’ll look to this invaluable collective wisdom for the answer.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) shareholders have witnessed an increase in hedge fund sentiment in recent months. MRTX was in 27 hedge funds’ portfolios at the end of the fourth quarter of 2018. There were 24 hedge funds in our database with MRTX positions at the end of the previous quarter. Our calculations also showed that MRTX isn’t among the 30 most popular stocks among hedge funds.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

Felix Baker - Baker Bros.

We’re going to take a look at the fresh hedge fund action regarding Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Hedge fund activity in Mirati Therapeutics, Inc. (NASDAQ:MRTX)

At Q4’s end, a total of 27 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 13% from the second quarter of 2018. The graph below displays the number of hedge funds with bullish position in MRTX over the last 14 quarters. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).

MRTX_apr2019

The largest stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX) was held by venBio Select Advisor, which reported holding $203.5 million worth of stock at the end of September. It was followed by Baker Bros. Advisors with a $106.6 million position. Other investors bullish on the company included Cormorant Asset Management, Farallon Capital, and Deerfield Management.

With a general bullishness amongst the heavyweights, some big names have jumped into Mirati Therapeutics, Inc. (NASDAQ:MRTX) headfirst. EcoR1 Capital, managed by Oleg Nodelman, created the biggest position in Mirati Therapeutics, Inc. (NASDAQ:MRTX). EcoR1 Capital had $27.5 million invested in the company at the end of the quarter. Albert Cha and Frank Kung’s Vivo Capital also made a $10.7 million investment in the stock during the quarter. The following funds were also among the new MRTX investors: Joseph Edelman’s Perceptive Advisors, D. E. Shaw’s D E Shaw, and Minhua Zhang’s Weld Capital Management.

Let’s check out hedge fund activity in other stocks similar to Mirati Therapeutics, Inc. (NASDAQ:MRTX). These stocks are Employers Holdings, Inc. (NYSE:EIG), G-III Apparel Group, Ltd. (NASDAQ:GIII), Enanta Pharmaceuticals Inc (NASDAQ:ENTA), and Atrion Corporation (NASDAQ:ATRI). All of these stocks’ market caps match MRTX’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
EIG 18 77399 3
GIII 13 103115 -4
ENTA 20 204695 -1
ATRI 10 81331 -1
Average 15.25 116635 -0.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 15.25 hedge funds with bullish positions and the average amount invested in these stocks was $117 million. That figure was $610 million in MRTX’s case. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is the most popular stock in this table. On the other hand Atrion Corporation (NASDAQ:ATRI) is the least popular one with only 10 bullish hedge fund positions. Compared to these stocks Mirati Therapeutics, Inc. (NASDAQ:MRTX) is more popular among hedge funds. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on MRTX as the stock returned 46.1% and outperformed the market by an even larger margin. Hedge funds were clearly right about piling into this stock relative to other stocks with similar market capitalizations.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...